These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27249715)

  • 1. Current State of Immune-Based Therapies for Glioblastoma.
    Lim M; Weller M; Chiocca EA
    Am Soc Clin Oncol Educ Book; 2016; 35():e132-9. PubMed ID: 27249715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state of immunotherapy for glioblastoma.
    Lim M; Xia Y; Bettegowda C; Weller M
    Nat Rev Clin Oncol; 2018 Jul; 15(7):422-442. PubMed ID: 29643471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations in glioblastoma: potential targets for immunotherapy.
    Haque A; Banik NL; Ray SK
    Prog Mol Biol Transl Sci; 2011; 98():187-234. PubMed ID: 21199773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for brain tumors: obstacles and perspectives].
    Migliorini D; Dietrich PY
    Rev Med Suisse; 2016 Apr; 12(516):828-31. PubMed ID: 27281940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
    Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
    Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
    Johanns TM; Dunn GP
    Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel vaccines for glioblastoma: clinical update and perspective.
    Winograd EK; Ciesielski MJ; Fenstermaker RA
    Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
    Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of immunotherapy and gene therapy for high-grade gliomas.
    Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
    Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of glioblastoma immunotherapy.
    Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
    J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy advances for glioblastoma.
    Reardon DA; Freeman G; Wu C; Chiocca EA; Wucherpfennig KW; Wen PY; Fritsch EF; Curry WT; Sampson JH; Dranoff G
    Neuro Oncol; 2014 Nov; 16(11):1441-58. PubMed ID: 25190673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The network of immunosuppressive pathways in glioblastoma.
    Mangani D; Weller M; Roth P
    Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.